. 2015 Mar 4;92(3):486–491. doi: 10.4269/ajtmh.14-0231

Table 2.

Patterns of neutralization antibody to DENV in 10- to 18-year-olds with IgG anti-DENV at enrollment in Puerto Rico in 2007

Anti-DENV neutralization patterns^* at enrollment	Age in years, n (%)				Total
Anti-DENV neutralization patterns^* at enrollment	10–11	12–13	14–15	16–18	Total
Negative for anti-DENV IgG^†	8 (15.4)	8 (16.5)	7 (32.7)	3 (15.4)	26 (19.6)^‡
Past DENV infection, single serotype	15 (28.5)	14 (25.7)	9 (26.1)	8 (30.6)	46 (27.5)^§
DENV-1^¶	0	1 (12.2)	0	2 (19.5)	3 (7.4)^∥
DENV-2^¶	1 (4.9)	6 (42.2)	2 (18.1)	1 (9.8)	10 (19.9)^**
DENV-3^¶	11 (75.3)	5 (37.3)	5 (47.5)	3 (51.1)	24 (53.8)^††
DENV-4^¶	3 (19.7)	2 (8.3)	2 (34.3)	2 (19.6)	9 (18.9)^‡‡
Past DENV infection, serotype undetermined	29 (56.1)	33 (57.8)	17 (41.3)	19 (53.9)	98 (52.9)^§§
Total	52	55	33	30	170

Calibration weighting was applied to the calculation of all proportions.

MNT was used to detect anti-DENV neutralization antibodies in enrollment specimens with a positive IgG anti-DENV ELISA result.

^†

Enrollment specimens with a negative single-dilution (1:100) IgG anti-DENV ELISA result did not receive additional testing.

^‡

95% CI = 13.6–27.4%.

^§

95% CI = 13.6–27.4%.

^¶

Predominant serotype; numbers in parentheses represent the percentages of the total for that past single-serotype DENV infection pattern by age group.

^∥

95% CI = 3.2–16.3%.

^**

95% CI = 10.5–34.3%.

^††

95% CI = 40.4–66.6%.

^‡‡

95% CI = 10.2–32.4%.

^§§

95% CI = 46.5–59.3%.